

Personalized medicine approach to osteoporosis management in women: integrating genetics, pharmacogenomics, and precision treatments

Seyi Samson Enitan^{1*}, Esther Ngozi Adejumo¹, John Osaigbovoh Imaralu², Ayodele Ademola Adelakun¹, Oluwakemi Anike Ladipo³, Comfort Bosede Enitan³

¹Department of Medical Laboratory Science, Babcock University, Ilishan-Remo 121103, Nigeria. ²Department of Gynaecology and Obstetrics, Babcock University Teaching Hospital, Ilishan-Remo 121103, Nigeria. ³Department of Chemical Pathology, Babcock University Teaching Hospital, Ilishan-Remo 121103, Nigeria.

*Corresponding to: Seyi Samson Enitan, Department of Medical Laboratory Science, Babcock University, PMB 4003, Ilishan-Remo 121103, Nigeria. E-mail: enitans@babcock.edu.ng.

Author contributions

SSE and ENA: Conceptualization and writing of the original draft, critical revision, and final approval of the submitted version. JOI and AAA: Conceptualization of the original draft, critical revision of the submitted version, and final approval. OAL and CBE: Conceptualization of the original draft, critical revision, and final approval of the submitted version.

Competing interests

The authors declare no conflicts of interest.

Acknowledgments

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Peer review information

Clinical Research Communications thanks De-Qing Chen and other anonymous reviewers for their contribution to the peer review of this paper.

Abbreviations

HCPs, healthcare providers; DXA, dual-energy X-ray absorptiometry; SERMs, selective estrogen receptor modulators; BMD, bone mineral density; CYP, cytochrome P450 enzymes.

Citation

Enitan SS, Adejumo EN, Imaralu JO, Adelakun AA, Ladipo OA, Enitan CB. Personalized medicine approach to osteoporosis management in women: integrating genetics, pharmacogenomics, and precision treatments. *Clin Res Commun*. 2023;6(3):18. doi: 10.53388/CRC2023018.

Executive editor: Xin-Yun Zhang.

Received: 29 June 2023; Accepted: 23 August 2023; Available online: 29 August 2023.

© 2023 By Author(s). Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license. (<https://creativecommons.org/licenses/by/4.0/>)

Abstract

Osteoporosis has emerged as a significant health issue among postmenopausal women. Addressing this concern necessitates a multifaceted approach encompassing genetics, pharmacogenomics, bone turnover markers, lifestyle factors, concurrent medical conditions, biomarkers, and advanced imaging techniques. Nonetheless, challenges in terms of cost-effectiveness and ethical considerations do exist. Fortunately, the convergence of technological progress and research endeavors offers a promising trajectory. The integration of genetic testing and pharmacogenomics into clinical practice holds substantial potential. This integration empowers healthcare professionals to forecast treatment responses and pinpoint individuals with elevated susceptibility, thereby enabling the implementation of tailored and efficacious interventions that optimize outcomes – personalized medicine. Given the intricate nature of osteoporosis, personalized strategies stand to greatly benefit women grappling with this condition. Further research and collaborative efforts are imperative to propel advancements within this domain, paving the way for further breakthroughs.

Keywords: osteoporosis; management; personalized medicine; pharmacogenomics; women

Introduction

Osteoporosis is an insidious and potentially fatal disorder, with growing concern among women globally [1]. This condition, characterized by a reduction in bone density and an increased risk of fractures, is particularly prevalent among postmenopausal women [2, 3], highlighting the significance of oestrogens in bone metabolism. Personalized medicine or precision medicine is the application of an individual's characteristics – such as genetic factors, environment, lifestyle and medical history – to customize treatment and preventive strategies for them, rather than relying on a 'one-size-fits-all' solution [4]. The advantages of personalized medicine are numerous. By considering an individual's biological and health information, the chances of successful treatment are optimized, the likelihood of adverse reactions is reduced and healthcare costs can be reduced. Moreover, this approach facilitates an active role for patients in healthcare decisions; understanding and respecting their own individual needs [5].

Personalized medicine is revolutionizing osteoporosis management in women. Risk assessment tools analyzing age, lifestyle habits, medical history, and genetic predisposition enable healthcare providers (HCPs) to determine a patient's susceptibility to fractures. Furthermore, genetic profiling allows for tailored treatments, which can bring greater success and positive health outcomes. As a powerful tool in osteoporosis management, personalized medicine offers HCPs detailed guidance to select the most effective treatment options [5].

The unique blend of genetic and environmental variables has opened up unprecedented opportunities for personalizing osteoporosis management. Lifestyle practices such as diet, physical activity, smoking, and alcohol use all have a significant impact on bone health; thus lifestyle modification is a crucial element of the treatment strategy. To meet individual patient requirements, HCPs are now able to provide personalized recommendations regarding calcium and vitamin D intake along with individualized exercise regimens [6]. Moreover, the introduction of high-resolution imaging techniques, such as dual-energy X-ray absorptiometry (DXA) and high-resolution peripheral quantitative computed tomography, has allowed HCPs to assess bone mineral density and microarchitectural strength with remarkable accuracy [7]. This detailed information provides vital insights into an individual's fracture risk and treatment response, offering unprecedented opportunities for individualized decision-making [8].

The remarkable proliferation of novel pharmacotherapies has opened up exciting possible treatment options for osteoporosis. Personalized medicine, which draws on various features such as drug interactions, side effects, co-morbidities, and more, puts patients in control in making the best selection of therapy. For instance, post-menopausal women can benefit from such drugs as bisphosphonates, selective estrogen receptor modulators (SERMs) and monoclonal antibodies [9].

Conventional osteoporosis management has largely focused on pre-defined drugs based on bone density and clinical probabilities. When managing this debilitating condition, it is necessary to consider a holistic approach, taking into consideration all the potential complications. This includes taking preventive measures, making lifestyle changes, and various treatments that can help women live more fulfilling lives. However, personalized medicines have highlighted the importance of genetics and pharmacogenomics in highlighting treatment options and pinpointing potential pitfalls [10].

This review explored the personalized medicine approach to osteoporosis management in women and the impact of genetics, pharmacogenomics and precision treatment integration on patient outcomes. With a deeper understanding, it is now possible to overturn conventional practices and truly revolutionize the management of this debilitating disease.

Classification and consequences of osteoporosis

Osteoporosis is categorized into primary (including type I and type II) and secondary forms. Primary osteoporosis primarily affects post-menopausal women, as well as men and women over the age of 70, due to the natural process of aging. Secondary osteoporosis, on the other hand, is triggered by various factors such as diseases, treatments, or idiopathic reasons. Secondary osteoporosis can be caused by systemic diseases, endocrine disorders, and malignant neoplasms, among others. Additionally, chronic use of glucocorticoids, certain lifestyle conditions, habits, and major depression also contributes to the pathogenesis of osteoporosis [11, 12].

Osteoporosis is a serious debilitating condition that primarily affects women, often after menopause, due to changes in estrogen levels and various other risk factors. Characterized by decreased bone density and an increased risk of fractures, osteoporosis may have numerous debilitating effects, such as chronic pain, physical disability, mental health issues, and enormous financial consequences. Some of the physical consequences include fractures of the wrist, ankle, hip, and vertebrae [3, 13].

The burden of osteoporosis and associated risk factors

Globally, about two hundred million women suffer from osteoporosis. It is essential to emphasize that fracture is the most significant complication of osteoporosis. According to projections by Shen et al. [14], it is anticipated that by 2050, the global occurrence of hip fractures will surge by 310% in men and 240% in women. It is also important to note that the risk of developing osteoporosis is determined by various lifestyle and medical conditions [15]. This includes genetics, inadequate intake of calcium and vitamin D, sedentariness, smoking, and excessive alcohol consumption; as well as specific medical conditions such as hyperthyroidism and rheumatoid arthritis, and long-term use of certain drugs such as corticosteroids [16–18].

Early detection and diagnosis of osteoporosis

Early detection and diagnosis of osteoporosis are important in avoiding and management of fractures. Though it remains asymptomatic until a fracture occurs, identifying those at risk allows HCPs to intervene and halt the progression of the disorder [9]. To determine the signs of osteoporosis, DXA scans permit HCPs to assess a patient's bone mineral density (BMD), producing a T-score according to comparisons with the healthy BMD of a youthful adult with the same sex. A T-score of less than –2.5 is an indicator of osteoporosis, whereas scores between –1 and –2.5 point to the potential onset of osteopenia, precursor to osteoporosis [19]. Utilizing clinical risk assessment tools such as the Fracture Risk Assessment Tool, HCPs can assess the fracturing risks of an individual depending on age, sex, medical history, along with extra lifestyle elements. Moreover, quantitative ultrasound and peripheral DXA measurements - which measure bone mineral density in peripheral sites, such as the heel or wrist - can be advantageous for identifying osteoporosis [9].

However, clinicians should bear in mind that they should not rely solely on BMD assessments when evaluating the disease, but rather consider a comprehensive evaluation including medical and physical details, risk factors, and serum calcium, vitamin D, or other components relevant to bone loss. Early detection of osteoporosis is essential in order to limit its destructive impact [20, 21].

Genetics and osteoporosis risk assessment

Genetic factors considerably make a contribution to the development of osteoporosis [22]. Genome-wide association studies have recognized numerous genetic variants related to bone mineral density and fracture threat. Integrating genetic facts into osteoporosis management allows physicians to pick out people at high risk and put into effect appropriate preventive measures. Polygenic risk scores, derived from multiple genetic variants may be used to assess an

individual's genetic susceptibility to osteoporosis. These scores may be a useful resource in identifying people who can be helped by advanced intervention or greater competitive treatment approach [19, 23].

Furthermore, genetic factors can have significant impact on BMD, bone turnover rates, and overall bone fitness. Several genes have been recognized as potential confounding factors to the risk of developing osteoporosis, with the most studied gene being the vitamin D receptor gene. Variations in the vitamin D receptor gene had been related to changes in bone metabolism and susceptibility to osteoporosis. In addition to the vitamin D receptor gene, other types of genes are involved in bone remodeling and regulation of calcium metabolism, consisting of ESR1, COL1A1, and LRP5, have additionally been linked to osteoporosis susceptibility. Genetic testing and risk evaluation can offer treasured insights into a person's predisposition to osteoporosis. By analyzing specific genetic markers, scientists can detect variations which can make a contribution to prolonged or decreased risk of developing disease [22]. This fact can help HCPs tailor prevention strategies and interventions to mitigate the risk of osteoporosis.

However, it's crucial to note that genetics is simply one piece of the puzzle when it comes to osteoporosis risk assessment. Lifestyle factors consisting of food regimen, physical activity, smoking, and alcohol intake additionally notably have an impact on bone fitness. Moreover, genetic testing by itself cannot definitively predict the improvement of osteoporosis, however instead gives broader information of an individual's genetic predisposition [24].

To assess osteoporosis risk in women, HCPs normally engage a multifactorial approach that considers genetic factors alongside medical risk factors, which includes age, body mass index, family records of fractures, and personal clinical records. Advancements in technologies which include genomics, proteomics, and virtual fitness have performed a widespread role in allowing customized medicinal drug. Genetic testing and analysis helps detect precise genetic variations or mutations which might impact on an individual's disease risk, drug metabolism, or treatment response. HCPs are thus able to make informed choices about which treatments or interventions are likely to have maximum efficacy or perhaps might also have adverse effects.

Pharmacogenomics and treatment response prediction

Pharmacogenomics is a discipline that examines how an individual's genetic makeup affects their response to specific drugs. It involves studying certain genetic variations which might affect drug metabolism, efficacy, and adverse reactions. In the context of osteoporosis management, pharmacogenomics help remedy response and optimize drug choice for each patient for higher effects [25].

Variations in genes associated with drug metabolism, transport, and drug targets might also influence response to certain drugs such as bisphosphonates or SERMs. Pharmacogenomic testing guides treatment choices with the aim of identifying sufferers who may be prone to adverse drug reactions or reduced efficacy with certain drugs. By tailoring treatment based on an individual's genetic profile, customized medication tactics can beautify treatment results and reduce the risk of adverse drug reactions [26].

Therapeutic drugs for osteoporosis, consisting of bisphosphonates, SERMs, and receptor activator of nuclear factor kappa-B ligand inhibitors, are normally prescribed to minimize the risk of fractures and improve bone health. However, the reaction to these drugs can vary amongst individuals, and a few sufferers may also suffer adverse effects or have suboptimal outcomes [27].

Genetic variations in key drug-metabolizing enzymes, drug transporters, and drug targets can have an impact on the pharmacokinetics and pharmacodynamics of osteoporosis medications. For instance, the cytochrome P450 enzymes (CYP) play an essential role in drug metabolism, together with the metabolism of bisphosphonates and SERMs. Polymorphisms in genes encoding these enzymes, consisting of CYP2C9 and CYP3A4, had been associated with variations in drug response and drug-associated adverse events [22].

Furthermore, genetic variations in genes involved in drug

transporters, consisting of ATP-binding cassette transporters, can affect the distribution and elimination of osteoporosis medications. These genetic variations might also effects drug bioavailability, tissue penetration, and clearance; ultimately influencing treatment efficacy and tolerability.

By figuring out unique genetic markers related to treatment response, pharmacogenomics helps HCPs tailor treatment. Genetic testing helps predict the probability of treatment success or identify individuals who may be more prone to unfavorable outcomes. This information can guide choice of treatment, dose adjustments, and personalized treatment plans. However, it is essential to note that pharmacogenomic testing remains an evolving discipline, and its recurring use in clinical practice for osteoporosis treatment is not yet widespread. Further studies and validation of genetic markers and their clinical utility are needed before extensive implementation.

Overall, pharmacogenomics affords the potentials to improve treatment outcomes in osteoporosis by way of predicting person responses to medications. Understanding a patient's genetic profile can be useful resource in choosing the most suitable treatment and optimizing dosing strategies. As the field of pharmacogenomics continues to advance, integrating genetic information into scientific decision-making may turn out to be a valuable tool for personalized osteoporosis management.

Precision treatments in osteoporosis management

In addition to genetics and pharmacogenomics, precision treatments in osteoporosis management contain a holistic approach that considers various affected patient-specific factors, inclusive of age, bone turnover markers, lifestyle, and coexisting clinical situations. The overall objective of precision medicine is to optimize treatment strategies by using tailoring interventions to an individual's unique clinical needs [28]. One emerging area in precision medicinal drug is using biomarkers to guide treatment choices. Bone turnover markers, which includes serum osteocalcin and C-terminal telopeptide of type I collagen, can provide insights into bone metabolism and predict treatment response. Monitoring these markers over time can assist clinicians assess the effectiveness of remedy and modify treatment thus [4]. Another promising aspect is the use of advanced imaging techniques to evaluate bone microarchitecture and strength. High-resolution peripheral quantitative computed tomography offers comprehensive details about bone quality, which is critical in identifying individuals at higher fracture risk and monitoring treatment response [5, 7].

In addition to genetics, personalized medicine considers other factors including lifestyle, weight loss plan, environment, and socio-economic factors. By considering a comprehensive set of record points, HCPs providers can increase personalized treatment plans that address an individual's unique conditions and optimize outcomes. For instance, personalized treatment may involve recommending particular life-style changes, nutritional modifications, targets remedies, or preventive strategies based totally on a person's specific risk profile [8, 29].

Lifestyle modifications

In addition to genetics and pharmacogenomics, life-style changes play an important role in osteoporosis management. These include regular weight-bearing physical activities (like walking, jogging, dancing, and strength training), good enough calcium and vitamin D intake, smoking cessation, and moderation of alcohol intake. Foods together with dairy products, leafy vegetable, fortified cereals, and fatty fish can provide optimal calcium and vitamin D. However, in a few cases, dietary supplements can be introduced under the guidance of a healthcare expert. Additionally, maintaining a healthy body weight and warding off crash diets mitigates the loss of bone mass. This emphasize that personalized medicine approach should encompass these life style factors to optimize treatment outcomes [30].

The combination of genetics, pharmacogenomics, and precision

treatments in osteoporosis management signifies a fundamental change in healthcare approach. This approach enables better decision-making, enhanced treatment plans, and superior results for patients. The relationship between genetics, pharmacogenomics and precision treatments in the management of osteoporosis is presented in Table 1.

Challenges and prospects of osteoporosis management

The management of osteoporosis employs a multifaceted strategies encompassing adjustments to one's lifestyle, medical treatments, and emerging therapeutic approaches. Despite progress in diagnosing and treating the condition, numerous challenges persist in effectively dealing with osteoporosis. These challenges involve instances where the condition is not accurately diagnosed, patients struggling to adhere to treatment plans, potential adverse effects of medications, the necessity for individualized interventions, integration of genetic testing and pharmacogenomic data into routine clinical practice, ensuring cost-effectiveness, and addressing ethical concerns associated with genetic testing and privacy (Table 2). Nevertheless, amid these difficulties, there are encouraging possibilities for enhancing osteoporosis management. These include the creation of new treatments, inventive diagnostic methods, and an increasing focus on comprehensive patient well-being [31].

Challenges of osteoporosis management

Effectively integrating genetic testing into routine clinical

practice

Integrating genetic testing into routine clinical practice calls for addressing certain problems:

Accessibility. Genetic testing may not be readily available or may be inexpensive for most patients. Access to genetic testing is restricted, in particular in certain regions or healthcare settings.

Interpretation. Genetic test results is complex and difficult to interpret for HCPs who might not have knowledge in genetics. Clear guidelines and resources are needed to help clinicians recognize and utilize genetic data correctly.

Clinical relevance. Identifying genetic variations associated with osteoporosis is just the first step. It is vital to set up the medical relevance of those findings and decide how they are able to guide treatment decisions and enhance patient outcomes.

Effectively integrating pharmacogenomic data into routine clinical practice

Integrating pharmacogenomic data into routine clinical practice requires addressing the following problems:

Limited evidence. Although research has identified a few genetic markers that could affect response to osteoporosis medicines, the field of pharmacogenomics in osteoporosis is emerging. Further studies are needed to establish strong associations among genetic variants and response to medication.

Implementation challenges. Incorporating pharmacogenomic data into clinical practice calls for overcoming sensible boundaries. This consists of growing standardized testing methods, ensuring the provision and affordability of genetic tests, and establishing suggestions for deciphering and using the results in treatment decision-making.

Table 1 Relationship between genetics, pharmacogenomics and precision treatments in the management of osteoporosis

Aspect	Genetics	Pharmacogenomics	Precision treatments
Definition	Study of individual genes and their variations.	Focuses on how genetics impact drug response.	Customized treatments based on genetic data.
Role in osteoporosis	Identifies genetic risk factors for osteoporosis.	Determines drug efficacy and adverse reactions.	Tailors treatments for optimal outcomes.
Genetic markers	Variants in genes like VDR, COL1A1, and LRP5.	SNPs related to drug metabolism and receptors.	Variants guide drug selection and dosages.
Fracture risk	Genetic variants influence bone density.	Genetic variations affect drug metabolism.	Selects medications to reduce fracture risk.
Drug response	Genetics impact how bones respond to therapies.	Determines how individuals metabolize drugs.	Chooses drugs that work best for each person.
Bisphosphonates	Genetic markers predict response to treatment.	Variations influence drug metabolism.	Selects bisphosphonates based on genetics.
Teriparatide	Genetic factors affect bone formation response.	Variants impact drug efficacy and safety.	Tailors Teriparatide use based on genetics.
Denosumab	Genetic variants may affect drug effectiveness.	Genetic factors influence drug metabolism.	Considers genetics when using Denosumab.
Hormone therapy	Genetics play a role in hormone interactions.	Genetic profile impacts hormone metabolism.	Customizes hormone therapy based on genes.
Vitamin D	Genetic variants influence vitamin D levels.	Variations affect how vitamin D is processed.	Adjusts vitamin D supplementation based on genetics.
Adverse reactions	Genetic makeup may lead to drug side effects.	Genetic factors impact drug tolerability.	Minimizes adverse effects based on genetics.

Table 2 Challenges and prospects in osteoporosis management

Aspect	Challenges	Prospects
Genetic variability	- Identifying relevant genetic markers for osteoporosis susceptibility is complex. - Limited understanding of gene-environment interactions.	- Advancements in genomics offer insights into personalized risk assessment. - Tailored interventions based on genetic predispositions.
Diagnostic tools	- Lack of efficient, low-cost methods for early diagnosis. Current diagnostic tools may not predict fracture risk accurately for all individuals.	- Emerging technologies like advanced imaging, biomarkers, and AI improve early detection and risk assessment. - More accurate fracture prediction models.
Treatment response	- Individual variations in treatment response. - One-size-fits-all approach might not yield optimal results for all patients.	- Pharmacogenomics helps predict drug responses, guiding personalized treatment choices. - Tailored exercise and nutrition plans for improved efficacy.
Data integration	- Difficulty in integrating diverse patient data (clinical, genetic, lifestyle). - Privacy concerns with sharing sensitive health data.	- Electronic health records and data sharing enable comprehensive patient profiles. - Secure data sharing protocols for research and analysis.
Lifestyle factors	- Challenges in motivating patients to adopt and sustain lifestyle changes. - Personal preferences and cultural factors influence adherence.	- Personalized lifestyle recommendations based on cultural, social, and individual preferences. - Behavioral interventions tailored to patient motivations.
Cost and access	- High costs associated with personalized diagnostics and treatments. - Limited access to advanced medical technologies in some regions.	- Increasing affordability of genetic testing and diagnostic tools. - Telemedicine expanding access to expert consultations and guidance.
Patient adherence	- Difficulty in ensuring patient compliance with personalized treatment plans. - Lifestyle changes and medication schedules can be challenging to follow.	- Personalized education and support systems enhance patient understanding and commitment. - Behavioral interventions tailored to individual needs.
Long-term monitoring	- Limited tools for continuous monitoring of treatment effectiveness and disease progression. - Resource constraints for long-term follow-up.	- Wearable devices and remote monitoring enable real-time tracking of health parameters. - Telehealth facilitates ongoing care without geographical limitations.
Integration of data sources	- Fragmented data across different healthcare providers and systems. - Difficulty in harmonizing data for comprehensive analysis.	- Implementation of interoperable health data systems for seamless information exchange. - AI-driven analytics for integrated data interpretation.
Ethical considerations	- Balancing privacy concerns with data utilization for personalized treatment.	- Development of robust data anonymization techniques to protect patient privacy.

Treatment selection and optimization. Pharmacogenomic data has the ability to guide drug selection and dosage optimization for individuals with osteoporosis. However, translating genetic data into actionable treatment decisions requires complete knowledge and tools that are easily accessible to healthcare givers [32, 33].

Ensuring cost effectiveness

Cost effectiveness in osteoporosis management refers back to the balance among the fees associated with diagnosing, treating, and preventing osteoporosis, and health outcomes achieved as a result. It is a major challenge because osteoporosis is a chronic condition that requires long term management, and the cost of drugs, diagnostic tests, and interventions may be significant [34].

There are several factors that contribute to the challenge of ensuring cost effectiveness in osteoporosis management:

Diagnostic assessments. Osteoporosis is usually diagnosed via bone density testing, along with DXA. These tests may be expensive, and the fees can also vary depending at the healthcare setting and location. Ensuring cost effectiveness entails comparing the suitable utilization of diagnostic tests and considering other opportunity, more cost-effective methods of screening and diagnosing osteoporosis [20]. **Medications.** Medications (like bisphosphonates, selective estrogen receptor modulators, and monoclonal antibodies) are essential component of osteoporosis management. These medicinal drugs can be expensive, especially for prolong use. Balancing the cost of medicinal drugs with their effectiveness and potential adverse effects

is vital to ensure cost effectiveness [20, 28].

Treatment adherence. Osteoporosis management calls for long-time period adherence to medication regimens and lifestyle adjustments. However, poor adherence is a common challenge and can cause suboptimal effects and increased costs. Strategies to improve adherence, along with patient enlightenment, regular follow-up, and reminder systems, are critical to maximize cost effectiveness [6, 20].

Fracture prevention strategies. The aim of osteoporosis management is to prevent fractures, being the gravest consequence of the disease. Implementing fracture prevention strategies, which include fall prevention programs and workout interventions, may be cost-effective by decreasing the incidence of fractures and the related healthcare costs.

Health economics evaluations. Conducting health economics evaluations, consisting of cost-effectiveness analyses or cost utility analyses, can help verify the cost of different osteoporosis management interventions. These evaluations consider both the cost and health outcomes associated with numerous treatment options and informs decision-making to prioritize cost-effective interventions [35].

Ethical considerations associated with genetic testing and privacy

Informed consent. Genetic testing need to be conducted with the informed consent of the individual. They should understand the reason, potential risks, and benefits of the test, in addition to the implications of the results.

Psychological impact. The results of genetic testing can have some critical psychological implications. Discovering an elevated genetic risk for osteoporosis can also cause tension, stress, or even discrimination in certain circumstances. Appropriate counseling and support services must be available to individuals undergoing genetic testing.

Genetic discrimination. Genetic information can potentially be misused to discriminate against some people by their employers or insurance companies. Protecting individuals from such discrimination calls for the implementation of legal safeguards and privacy policies, which includes the Genetic Information Nondiscrimination Act in the United States.

Data security. Genetic data is extremely personal and should be protected against unauthorized access, use, or disclosure. Robust security measures ought to be in place to safeguard genetic records from hacking and breaches.

Data sharing. Research efforts usually depend on sharing genetic data to improve clinical outcome and scientific comprehension. However, suitable measures need to be taken to de-identify and anonymize data to guard the privacy of people. Strict recommendations and protocols for information sharing must be established to make certain accountable and ethical use of genetic data [36].

Third-party access. Genetic testing companies may accumulate and keep people's genetic information. Ethical concerns rise up when these organizations shall or sell information to third parties, like pharmaceutical companies or research institutes. Transparent guidelines and express consent mechanisms are vital to ensure people have control over how their genetic information is used.

Way forward in improving the management of osteoporosis

Prevention and early intervention. Emphasizing prevention and early intervention can reduce the burden of osteoporosis-associated fractures and their related costs. Promoting bone fitness through way of life modifications, adequate calcium and vitamin D intake, and regular weight-bearing exercise prevents osteoporosis development and progression [37].

Screening and risk assessment. Implementing targeted screening and risk assessment strategies can optimize using diagnostic tests, ensuring that they may be applied for people who are most likely to benefit. Identifying high-risk individuals for osteoporosis earlier on facilitates timely interventions and prevents pointless testing in low-risk people [20].

Treatment guidelines and formulary management. Developing

evidence-based treatment guidelines and formulary management guides HCPs in selecting cost-effective medicinal drugs. Consideration of timely alternatives and negotiating drug pricing can help reduce medication costs without compromising patient outcomes [20].

Patient education and shared decision-making. Educating women about osteoporosis, its management, and the importance of treatment adherence can enhance patient engagement and shared decision-making. Informed patients are more likely to recognize the benefits and dangers of different interventions and make choices that align with their choices and values [38, 39].

Collaboration and coordination. Enhancing collaboration between researchers, HCPs, funders, and policymakers can promote the exchange of knowledge and best practices in osteoporosis management. This collaborative approach develops of cost-effective pathways and the implementation of reimbursement regulations that incentivize highest quality control strategies.

Establishment of a robust ethical framework. Addressing ethical concerns by way of organizing a robust ethical framework, guidelines, and regulations surrounding genetic testing for osteoporosis is very important. These have to prioritize informed consent, psychological support, privacy safety, data protection, and strict rules at the use and sharing of genetic information. Balancing the advantages of genetic testing with privacy concerns and ensuring responsible and moral practices is vital for advancing osteoporosis care and management.

The future prospects of osteoporosis management

The future of personalized medicine in osteoporosis care and management appears promising. Advancements in technology, which includes next-generation sequencing and improved data evaluation strategies, are making genetic testing readily available and affordable. As our knowledge of the genetics in osteoporosis improves, we anticipate the improvement of targeted therapies that especially address the underlying genetic factors contributing to the disease [31]. Furthermore, the combination of digital health data and genomic data provide clinicians with treasured insights into a woman's genetic predisposition, treatment history, and response to interventions. This comprehensive strategy can enhance clinical decision-making and permit the implementation of personalized treatment plans tailored to each patient's unique clinical needs [5].

Collaboration between researchers, clinicians, and pharmaceutical companies is vital for further advancements in personalized medicine for osteoporosis. Large-scale collaborative studies and medical trials helps validate the use of genetic and pharmacogenomic testing in predicting treatment response and optimizing results. Moreover, ongoing studies efforts are targeted at identifying additional genetic variations associated with osteoporosis and fracture risk, thus enhancing our ability to predict and manage the disease with a personalized approach [40].

Conclusion

In conclusion, personalized medicine has the potential to revolutionize the management of osteoporosis in women by means of tailoring treatment strategies to individual patient's need. By incorporating risk assessment tool, genetic profiling, lifestyle adjustments, advanced imaging technologies, and targeted pharmacological interventions, healthcare providers can optimize treatment outcomes and reduce the burden of osteoporosis-related fractures in women. However, it is essential to observe that personalized medicine is an evolving area, and there are nevertheless challenges to be addressed. It calls for access to comprehensive and accurate health data, advanced technologies, and specialized expertise data analysis and interpretation. Ethical concerns, which include patient privacy and consent, also need to be cautiously navigated. While challenges remain, further studies, technological advancements, and collaborative efforts will power the sector forward, enabling a more personalized and effective approach to osteoporosis management in women and ultimately improving their quality of life.

References

- Cook A, Moss T, Malaya C. Osteoporosis: A Review for Chiropractic Clinicians.. *J Contemporary Chiropr* 2023;6(1):29–51. Available at: <https://journal.parker.edu/index.php/jcc/article/view/261>
- Lorentzon M, Johansson H, Harvey NC, et al. Osteoporosis and fractures in women: the burden of disease. *Climacteric* 2021;25(1):4–10. Available at: <http://doi.org/10.1080/13697137.2021.1951206>
- Al Zadjali F, Brooks J, O'Neill TW, Stanmore E. Experiences of postmenopausal osteoporosis: a narrative review. *Disabil Rehabil* 2023;1–13. Available at: <http://doi.org/10.1080/09638288.2023.2169770>
- Findlay MC, Cole KL, Kundu M, Chase M, Johansen, Luck-Wold B. Osteoporosis Management: A Suggested Algorithm for Optimizing Spine Surgery Outcomes in Osteoporotic Patients. *Clin Trials Clin Res* 2023;2(1). Available at: <https://clinicsearchonline.org/article/osteoporosis-management-a-suggested-algorithm-for-optimizing-spine-surgery-outcomes-in-osteoporotic-patients>
- Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. *J Pers Med* 2023;13(3):422. Available at: <http://doi.org/10.3390/jpm13030422>
- Wang H, Luo Y, Wang H, Li F, Yu F, Ye L. Mechanistic advances in osteoporosis and anti-osteoporosis therapies. *MedComm* 2023;4(3):e244. Available at: <http://doi.org/10.1002/mco2.244>
- Wysocki MA, Doyle ST. Advancing Osteoporosis Evaluation Procedures: Detailed Computational Analysis of Regional Structural Vulnerabilities in Osteoporotic Bone. *J Pers Med* 2023;13(2):321. Available at: <http://doi.org/10.3390/jpm13020321>
- Sheppard AJ, Paravastu SS, Wojnowski NM, et al. Emerging Role of 18F-NaF PET/Computed Tomographic Imaging in Osteoporosis. *PET Clin* 2023;18(1):1–20. Available at: <http://doi.org/10.1016/j.ppet.2022.09.001>
- Al-Saleh Y, Sulimani R, Sabico S, et al. Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society. *Arch Osteoporos* 2023;18(1):75. Available at: <http://doi.org/10.1007/s11657-023-01242-w>
- Haarhaus M, Aaltonen L, Cejka D, et al. Management of fracture risk in CKD—traditional and novel approaches. *Clin Kidney J* 2022;16(3):456–472. Available at: <http://doi.org/10.1093/ckj/sfac230>
- Marcucci G. Rare causes of osteoporosis. *Clin Cases Miner Bone Metab* 2015;12(2):151–156. Available at: <http://doi.org/10.11138/ccmbm/2015.12.2.151>
- Wang L-T, Chen L-R, Chen K-H. Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview. *Int J Mol Sci* 2023;24(6):5814. Available at: <http://doi.org/10.3390/ijms24065814>
- de Sire A, Lippi L, Marotta N, et al. Impact of Physical Rehabilitation on Bone Biomarkers in Non-Metastatic Breast Cancer Women: A Systematic Review and Meta-Analysis. *Int J Mol Sci* 2023;24(2):921. Available at: <http://doi.org/10.3390/ijms24020921>
- Shen Y, Huang X, Wu J, et al. The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990–2019. *Front Endocrinol* 2022;13:882241. Available at: <http://doi.org/10.3389/fendo.2022.882241>
- Sharif K, Tsur AM, Ben-Shabat N, Watad A, Cohen AD, Amital H. The risk of osteoporosis in patients with ankylosing spondylitis—A large retrospective matched cohort study. *Med Clin (Barc)* 2023;160(9):373–378. Available at: <http://doi.org/10.1016/j.medcle.2022.10.020>
- Diffenderfer BW, Wang Y, Pearman L, Pyrih N, Williams SA. Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture. *J Am Acad Orthop Surg* 2023;31(6):e327–e335. Available at: <http://doi.org/10.5435/JAAOS-D-22-00476>
- Gadgaard NR, Varnum C, Nelissen RGHH, Vandenbroucke-Grauls C, Sørensen HT, Pedersen AB. Comorbidity and risk of infection among patients with hip fracture: a Danish population-based cohort study. *Osteoporos Int* 2023. Available at: <http://doi.org/10.1007/s00198-023-06823-6>
- Younesi Asl L, Kashanian M, Najmi Z, Mahdavi A, SafarpourLima Z. Risk factors of osteoporosis and osteopenia in postmenopausal women based on the L2–L4 BMD T score of the lumbar spine: a study in Iran. *Gynecol Endocrinol* 2023;39(1):2205959. Available at: <http://doi.org/10.1080/09513590.2023.2205959>
- Xiao X, Wu Q. The clinical utility of the BMD-related comprehensive genome-wide polygenic score in identifying individuals with a high risk of osteoporotic fractures. *Osteoporos Int* 2023;34(4):681–692. Available at: <http://doi.org/10.1007/s00198-022-06654-x>
- Sabri SA, Chavarria JC, Ackert-Bicknell C, Swanson C, Burger E. Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment. *Orthopedics* 2023;46(1):e20–e26. Available at: <http://doi.org/10.3928/01477447-20220719-03>
- Wáng YXJ. A summary of our recent evidence-based works on radiographic diagnostics of prevalent osteoporotic vertebral fracture in older men and women. *Quant Imaging Med Surg* 2023;13(3):1264–1285. Available at: <http://doi.org/10.21037/qims-22-1411>
- Ralston SH. Genetic determinants of osteoporosis. *Curr Opin Rheumatol* 2005;17(4):475–479. Available at: <http://doi.org/10.1097/01.bor.0000166385.62851.92>
- Simona A, Song W, Bates DW, Samer CF. Polygenic risk scores in pharmacogenomics: opportunities and challenges—a mini review. *Front Genet* 2023;14:1217049. Available at: <http://doi.org/10.3389/fgene.2023.1217049>
- Yuan J, Tickner J, Mullin BH, et al. Advanced Genetic Approaches in Discovery and Characterization of Genes Involved With Osteoporosis in Mouse and Human. *Front Genet* 2019;10:288. Available at: <http://doi.org/10.3389/fgene.2019.00288>
- Riancho JA, Hernández JL. Pharmacogenomics of osteoporosis: a pathway approach. *Pharmacogenomics* 2012;13(7):815–829. Available at: <http://doi.org/10.2217/pgs.12.50>
- Mousa S, Greene R, Ardawi M, Qari M, Mousa S. Pharmacogenomics in osteoporosis: Steps toward personalized medicine. *Pharmacogenomics Pers Med* 2009;2:69–78. Available at: <http://doi.org/10.2147/PGPM.S5803>
- Qaseem A, Hicks LA, Etzeandia-Ikobaltzeta I, Shamliyan T, Cooney TG. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. *Ann Intern Med* 2023;176(2):224–238. Available at: <http://doi.org/10.7326/M22-1034>
- Choong DS, Tan NC, Koh YLE, Leong CK, Sankari U, Koh KH. Osteoporosis management by primary care physicians in Singapore: a survey on osteoporosis guidelines utilisation and barriers to care. *Arch Osteoporos* 2023;18(1):72. Available at: <http://doi.org/10.1007/s11657-023-01283-1>
- Solanki P, Ansari MohdD, Alam MohdI, Aqil Mohd, Ahmad FJ, Sultana Y. Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis. *Drug Deliv Transl Res* 2022;13(3):883–913. Available at:

- <http://doi.org/10.1007/s13346-022-01259-7>
30. Beaudart C, Boonen A, Li N, et al. Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. *Osteoporos Int* 2022;33(6):1335–1346. Available at: <http://doi.org/10.1007/s00198-022-06310-4>
 31. Mitchell BD, Yerges-Armstrong LM. The Genetics of Bone Loss: Challenges and Prospects. *J Clin Endocrinol Metab* 2011;96(5):1258–1268. Available at: <http://doi.org/10.1210/jc.2010-2865>
 32. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int* 2014;25(10):2359–2381. Available at: <http://doi.org/10.1007/s00198-014-2794-2>
 33. Amin U, McPartland A, O'Sullivan M, Silke C. An overview of the management of osteoporosis in the aging female population. *Womens Health (Lond)* 2023;19:174550572311766. Available at: <http://doi.org/10.1177/17455057231176655>
 34. Auais M, Angermann H, Grubb M, Thomas C, Feng C, Chu CH. The effectiveness and cost-effectiveness of clinical fracture-risk assessment tools in reducing future osteoporotic fractures among older adults: a structured scoping review. *Osteoporos Int* 2023;34(5):823–840. Available at: <http://doi.org/10.1007/s00198-022-06659-6>
 35. Rashki kemmak A, Reazpour A, Jahangiri R, Nikjoo S, Farabi H, Soleimanpour S. Economic burden of osteoporosis in the world: A systematic review. *Med J Islam Repub Iran* 2020;34:154. Available at: <http://doi.org/10.47176/mjiri.34.154>
 36. Huang I-C, Wu H-C, Lin C-L, Wang H-H. Development and Validation of the Osteoporosis Knowledge, Attitude, and Behaviors Questionnaire for Female Osteoporosis Patients in Taiwan: A Mediation Model. *Healthcare (Basel)* 2023;11(7):1023. Available at: <http://doi.org/10.3390/healthcare11071023>
 37. Tai T-W, Huang C-F, Huang H-K, et al. Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update. *J Formos Med Assoc* 2023;S0929-6646(23)00007-4. Available at: <http://doi.org/10.1016/j.jfma.2023.01.007>
 38. Dastmanesh S, Karimi M, Ghahremani L, Seif M, Zare E. A health communication campaign for prevention of osteoporosis in rural elderly women. *BMC Womens Health* 2023;23(1):124. Available at: <http://doi.org/10.1186/s12905-023-02282-7>
 39. Spångeus A, Willerton C, Enthoven P, Grahn Kronhed A-C. Patient Education Improves Pain and Health-Related Quality of Life in Patients with Established Spinal Osteoporosis in Primary Care—A Pilot Study of Short- and Long-Term Effects. *Int J Environ Res Public Health* 2023;20(6):4933. Available at: <http://doi.org/10.3390/ijerph20064933>
 40. Pirmohamed M. Pharmacogenomics: current status and future perspectives. *Nat Rev Genet* 2023;24(6):350–362. Available at: <http://doi.org/10.1038/s41576-022-00572-8>